It'll be interesting to see whether the assumption of some kind...

It'll be interesting to see whether the assumption of some kind of seasonality in quarter by quarter purchases is relevant for NXS's products now, in particular Q3 revenue. We might not be able to use that assumption now, I generally see 2019 and 2020 calendar years as a train slowly pulling out from the station, NXS just getting going. Now that NXS has it's products in over 1,600 US hospitals and their existing products are the kind of products that I would have thought would be used every day, will seasonality be relevant?

Judith's comments here (from page 4 of her Full year briefing transcript of 23/2/21, source ASX), in particular her comment about NXS's products being used more broadly now, is building confidence in the recovery of NXS. As always DYOR IMHO


The train has left the station, your going to have to run now to get on board.
Rounding bottom completed IMHO